Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 3 | Unknown | — |
The patient received the second dose of RabAvert seven days after the first dose and third dose 11 days after the first dose, for indication of postexposure prophylaxis; Case reference number US-BN-2025-001595 is a spontaneous case initially received from a consumer via agency (reference number: USBAV25-2376) on 24-Sep-2025 and concerns a 60-year-old male patient. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient was bitten by a bat. On 08-Sep-2025, also reported as day 0, the patient received the first RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration for post-exposure prophylaxis. . On 15-Sep-2025, seven days after the first dose, the patient received the second RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration (explicitly coded as 'Inappropriate schedule of vaccine administered'). On 19-Sep-2025, 11 days after the first dose, the patient received the third RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection, and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration (explicitly coded as 'Inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to RabAvert. No further information was provided.; Reporter's Comments: A 60-year-old male patient received the second dose of RabAvert seven days after the first dose and third dose 11 days after the first dose, for indication of post-exposure prophylaxis, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any of adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 60-year-old male patient received the second dose of RabAvert seven days after the first dose and third dose 11 days after the first dose, for indication of post-exposure prophylaxis, which is considered as inappropriate schedule of product administration. It was unknown if the patient experienced any of adverse events due to RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: none